A multicenter, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from active thyroid eye disease (TED)
The purpose of this study is to obtain information on the safety and effectiveness of an investigational drug called RV 001 in the treatment of Thyroid Eye Disease (TED).
Thyroid Eye Disease (TED)
1. Aged 18-75 years
2. Clinical diagnosis of Graves' disease associated with active TED within past 9 months
4. No previous medical or surgical therapy for TED, excluding local supportive measures.
18 - 75
Healthy Volunteers Needed
Duration of Participation
Approximately 18 months
Chad Sorenson -
River Vision Development Corporation
$50 per study related visit